[
  {
    "objectID": "quarto/analysis.html",
    "href": "quarto/analysis.html",
    "title": "The Financial Toxicity of Universal GLP-1 Receptor Agonists in US Adults Meeting FDA Eligibility for Incretin-Based Weight Management Therapies",
    "section": "",
    "text": "— CONSORT FLOW DIAGRAM DATA (2022 Cross-sectional Persons) —\nSTEP 1: Total MEPS Population (2022) | N = 22,431\nExclusion 1: Pediatric &lt; 18 | n = 4,330\nSTEP 2: Adult Population (Age &gt;= 18) | N = 18,101 (80.7%)\nExclusion 2: Does Not Meet FDA Eligibility (Not obese and not overweight with &gt;=1 qualifying weight-related comorbidity) | n = 13,046 (72.1%)\nSTEP 3: US Adults Meeting FDA Eligibility for Incretin-Based Weight Management Therapies | N = 5,055 (27.9%)\nExclusion 3: No GLP-1RA Therapy Exclusion (Universal Sample Retained) | n = 0\nSTEP 4: Broad FDA-Eligible Cohort | N = 5,055 (100.0%)\nExclusion 4: Uninsured/Other | n = 357 (7.1%)\nSTEP 5: Final Analytic Cohort (Valid Insurance) | N = 4,698 (92.9%)\n\n\n\n\n\n\n\nTable 1. Demographic and Clinical Characteristics of US Adults Eligible for Incretin-Based Weight Management Therapies.\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nCharacteristic\nOverall N = 63,173,236 (100%)1\nMedicaid or Dual Eligible N = 11,850,683 (19%)1\nMedicare N = 18,391,014 (29%)1\nPrivate/Commercial N = 32,931,540 (52%)1\n\n\n\n\nCurrent GLP-1 Receptor Agonist Use\n3,399,443 (5.4%)\n760,948 (6.4%)\n1,020,683 (5.5%)\n1,617,811 (4.9%)\n\n\nHypertension\n33,801,219 (54%)\n6,423,215 (54%)\n13,920,069 (76%)\n13,457,935 (41%)\n\n\nDyslipidemia\n33,124,731 (52%)\n6,096,618 (51%)\n13,911,529 (76%)\n13,116,585 (40%)\n\n\nType 2 Diabetes\n13,611,068 (22%)\n3,084,193 (26%)\n5,770,714 (31%)\n4,756,161 (14%)\n\n\nCardiovascular Disease\n15,258,341 (24%)\n3,201,027 (27%)\n7,728,520 (42%)\n4,328,794 (13%)\n\n\nObstructive Sleep Apnea\n\n\n\n\n\n\n\n\n\n\n    0\n63,173,236 (100%)\n11,850,683 (100%)\n18,391,014 (100%)\n32,931,540 (100%)\n\n\nAge Category\n\n\n\n\n\n\n\n\n\n\n    18-64 Years\n42,080,142 (67%)\n9,433,830 (80%)\n0 (0%)\n32,646,312 (99%)\n\n\n    65-74 Years\n13,386,646 (21%)\n1,543,108 (13%)\n11,571,758 (63%)\n271,780 (0.8%)\n\n\n    ≥75 Years\n7,706,448 (12%)\n873,745 (7.4%)\n6,819,256 (37%)\n13,447 (&lt;0.1%)\n\n\nSex\n\n\n\n\n\n\n\n\n\n\n    Female\n33,170,189 (53%)\n7,632,402 (64%)\n9,265,024 (50%)\n16,272,763 (49%)\n\n\n    Male\n30,003,048 (47%)\n4,218,281 (36%)\n9,125,990 (50%)\n16,658,777 (51%)\n\n\nRace and Ethnicity\n\n\n\n\n\n\n\n\n\n\n    White\n42,666,364 (68%)\n6,365,599 (54%)\n14,918,600 (81%)\n21,382,165 (65%)\n\n\n    Black\n8,237,098 (13%)\n2,464,050 (21%)\n1,745,728 (9.5%)\n4,027,320 (12%)\n\n\n    Hispanic or Latino\n8,432,173 (13%)\n2,400,421 (20%)\n1,184,557 (6.4%)\n4,847,196 (15%)\n\n\n    Other Race and Ethnicity\n3,837,601 (6.1%)\n620,613 (5.2%)\n542,129 (2.9%)\n2,674,859 (8.1%)\n\n\nAnnual Household Income\n\n\n\n\n\n\n\n\n\n\n    Low (&lt;125% FPL)\n8,675,921 (14%)\n5,053,633 (43%)\n1,802,145 (9.8%)\n1,820,143 (5.5%)\n\n\n    Middle (125%-400% FPL)\n26,743,063 (42%)\n5,838,992 (49%)\n8,422,643 (46%)\n12,481,428 (38%)\n\n\n    High (&gt;400% FPL)\n27,754,253 (44%)\n958,058 (8.1%)\n8,166,226 (44%)\n18,629,969 (57%)\n\n\nEmployment Status\n\n\n\n\n\n\n\n\n\n\n    Not Employed\n24,078,546 (38%)\n6,914,440 (59%)\n13,837,426 (75%)\n3,326,680 (10%)\n\n\n    Employed\n38,899,650 (62%)\n4,857,454 (41%)\n4,520,499 (25%)\n29,521,696 (90%)\n\n\n\n1 n (%)\n\n\nNotes: MEPS 2022 cross-sectional estimates. Values represent weighted national estimates for the FDA-Eligible Cohort. Obesity is defined as body mass index &gt;=30 kg/m^2 or a documented clinical diagnosis of obesity. Overweight is defined as body mass index 27.0-29.9 kg/m^2 with at least one qualifying weight-related comorbidity (hypertension, dyslipidemia, type 2 diabetes, cardiovascular disease, or obstructive sleep apnea). GLP-1RA indicates glucagon-like peptide-1 receptor agonist. Income categories are based on the Federal Poverty Level (FPL). Costs are reported in Jan 2026 US dollars.\n\n\n\n\n\n\n\n\n\n\n\n\nTable 2. Mean Annual Out-of-Pocket Health Care Expenditures Among US Adults Eligible for Incretin-Based Weight Management Therapies by Service Category and Demographic Subgroup.\n\n\n\n\n\n\n\n\n\n\nTotal Out-of-Pocket Expenditures\nPrescription Drugs\nHealth Insurance Premiums\nOutpatient and Office-Based Care\nInpatient Hospital Care\nOther Medical\n\n\n\n\nOverall Population\n\n\nOverall\n$4059 (3810-4324)\n$256 (230-285)\n$2634 (2464-2815)\n$551 (440-690)\n$61 (28-131)\n$557 (504-616)\n\n\nInsurance Type\n\n\nMedicaid or Dual Eligible\n$1133 (772-1662)\n$83 (62-111)\n$433 (306-614)\n$309 (--)\n$17 (--)\n$291 (175-482)\n\n\nMedicare\n$3490 (3165-3848)\n$450 (399-507)\n$1433 (1235-1663)\n$566 (442-725)\n$122 (--)\n$918 (808-1043)\n\n\nPrivate/Commercial\n$5429 (5083-5799)\n$209 (172-254)\n$4097 (3840-4371)\n$630 (470-843)\n$43 (30-60)\n$451 (398-510)\n\n\nAge Group\n\n\n18-64 Years\n$4468 (4146-4815)\n$175 (145-211)\n$3286 (3057-3532)\n$565 (413-772)\n$35 (24-50)\n$408 (351-473)\n\n\n65-74 Years\n$3301 (2962-3679)\n$397 (345-458)\n$1530 (1302-1798)\n$578 (425-786)\n$21 (12-38)\n$774 (652-920)\n\n\n≥75 Years\n$3141 (2658-3712)\n$452 (366-559)\n$991 (770-1277)\n$431 (332-559)\n$272 (--)\n$995 (822-1203)\n\n\nSex\n\n\nFemale\n$4031 (3719-4369)\n$248 (216-284)\n$2504 (2293-2735)\n$597 (440-811)\n$47 (34-66)\n$635 (553-729)\n\n\nMale\n$4089 (3791-4410)\n$265 (229-306)\n$2777 (2574-2996)\n$500 (360-695)\n$76 (--)\n$471 (418-531)\n\n\nIncome Level\n\n\nLow (&lt;125% FPL)\n$1976 (1441-2708)\n$156 (129-190)\n$897 (672-1199)\n$516 (194-1371)\n$8 (4-14)\n$399 (248-640)\n\n\nMiddle (125%-400% FPL)\n$3379 (3113-3667)\n$265 (221-317)\n$2143 (1921-2391)\n$368 (314-431)\n$105 (--)\n$499 (425-584)\n\n\nHigh (&gt;400% FPL)\n$5365 (4976-5784)\n$278 (240-322)\n$3650 (3388-3931)\n$739 (551-993)\n$35 (23-53)\n$663 (590-744)\n\n\nRace and Ethnicity\n\n\nWhite\n$4477 (4197-4776)\n$296 (267-329)\n$2844 (2633-3072)\n$616 (498-763)\n$78 (33-189)\n$642 (577-713)\n\n\nBlack\n$3102 (2369-4062)\n$249 (157-393)\n$1945 (1629-2322)\n$522 (--)\n$33 (14-80)\n$353 (281-445)\n\n\nHispanic or Latino\n$2884 (2434-3416)\n$110 (76-159)\n$2080 (1721-2514)\n$273 (181-411)\n$19 (9-40)\n$401 (240-673)\n\n\nOther Race and Ethnicity\n$4045 (3404-4805)\n$139 (96-201)\n$2989 (2421-3692)\n$504 (261-972)\n$19 (--)\n$393 (301-513)\n\n\n\nNotes: MEPS 2022 cross-sectional estimates. Values represent mean annual out-of-pocket (OOP) expenditures. Costs are reported in Jan 2026 US dollars. Confidence intervals (95%) were calculated using bootstrap-estimated standard errors (2000 replicates) and log-transformation to account for the right-skewed distribution of health care costs.\n\n\n\n\n\n\n\n\n\n\n\n\nTable 3. Financial Toxicity Under Universal GLP-1RA With TrumpRx Rational Buyer Cash Substitution.\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nBaseline (95% CI)\nUniversal GLP-1RA (95% CI)\n\nTrumpRx ($6,037/yr)\n\n\n\nRevised FT, % (95% CI)\nBenefiting, % (95% CI)\nBeneficiary Savings, $ (95% CI)\n\n\n\n\nOverall Population\n\n\nOverall Population\n18.0 (16.7-19.4)\n19.6 (18.2-21.1)\n19.6 (18.2-21.1)\n0.3 (0.1-0.6)\n$6110 (6091-6129)\n\n\nInsurance Type\n\n\nMedicaid or Dual Eligible\n32.6 (28.6-36.8)\n34.3 (30.3-38.5)\n34.3 (30.3-38.5)\n0.1 (--)\n$6087 (--)\n\n\nMedicare\n17.7 (15.2-20.5)\n20.3 (17.4-23.4)\n20.3 (17.4-23.4)\n0.5 (0.2-1.0)\n$6130 (--)\n\n\nPrivate/Commercial\n12.9 (11.2-14.8)\n13.9 (12.2-15.8)\n13.9 (12.2-15.8)\n0.3 (0.0-1.0)\n$6094 (--)\n\n\nAge Group\n\n\n18-64 Years\n17.0 (15.3-18.8)\n18.2 (16.5-20.0)\n18.2 (16.5-20.0)\n0.2 (0.0-0.7)\n$6094 (--)\n\n\n65-74 Years\n16.8 (13.9-20.0)\n18.9 (15.9-22.3)\n18.9 (15.9-22.3)\n0.5 (0.1-1.2)\n$6127 (--)\n\n\n≥75 Years\n25.7 (21.5-30.2)\n28.6 (24.2-33.3)\n28.6 (24.2-33.3)\n0.5 (0.1-1.3)\n$6121 (--)\n\n\nSex\n\n\nFemale\n21.3 (19.6-23.1)\n22.9 (21.1-24.7)\n22.9 (21.1-24.7)\n0.3 (0.1-1.0)\n$6107 (--)\n\n\nMale\n14.4 (12.7-16.3)\n16.0 (14.1-18.0)\n16.0 (14.1-18.0)\n0.3 (0.1-0.6)\n$6114 (--)\n\n\nIncome Level\n\n\nLow (&lt;125% FPL)\n75.0 (70.7-79.0)\n78.5 (74.4-82.2)\n78.5 (74.4-82.2)\n0.2 (0.0-0.8)\n$6137 (--)\n\n\nMiddle (125%-400% FPL)\n16.7 (14.6-19.0)\n19.2 (16.9-21.6)\n19.2 (16.9-21.6)\n0.3 (0.1-0.7)\n$6120 (--)\n\n\nHigh (&gt;400% FPL)\n1.5 (0.8-2.4)\n1.6 (0.9-2.5)\n1.6 (0.9-2.5)\n0.3 (0.0-1.1)\n$6093 (--)\n\n\nRace and Ethnicity\n\n\nWhite\n17.5 (15.8-19.4)\n19.0 (17.1-21.0)\n19.0 (17.1-21.0)\n0.4 (0.2-0.9)\n$6111 (6090-6131)\n\n\nBlack\n22.9 (18.9-27.3)\n24.6 (20.6-29.0)\n24.6 (20.6-29.0)\n0.0 (--)\n--\n\n\nHispanic or Latino\n17.0 (14.0-20.4)\n19.0 (15.8-22.5)\n19.0 (15.8-22.5)\n0.0 (--)\n--\n\n\nOther Race and Ethnicity\n15.2 (10.5-20.9)\n16.9 (12.0-22.7)\n16.9 (12.0-22.7)\n0.2 (--)\n$6087 (--)\n\n\n\nNotes: MEPS 2022 cross-sectional estimates. Financial toxicity is defined as annual out-of-pocket health care expenditures (including premiums) exceeding 20% of post-subsistence income. ‘Universal GLP-1RA’ assumes 100% adherence through insurance; TrumpRx applies a rational buyer minimum of insured vs cash prices with a $6,037 annual cap. Costs are reported in Jan 2026 US dollars. CIs for proportions are Korn-Graubard beta intervals based on bootstrap standard errors (2000 replicates). Cost CIs use bootstrap standard errors with log-transformation. ‘–’ = Suppressed due to statistical unreliability (insufficient sample size or variance instability).\n\n\n\n\n\n\n\n\n\n\n\n\nTable 4. Projected Incidence of Financial Toxicity Among Medicare Beneficiaries Under Universal GLP-1 Receptor Agonist Adherence and Inflation Reduction Act Scenarios.\n\n\n\n\n\n\n\n\n\n\nBaseline Utilization, % (95% CI)\nUniversal GLP-1 Receptor Agonist Adherence, % (95% CI)\nInflation Reduction Act Implementation, % (95% CI)\nAbsolute Risk Reduction, %\nRelative Risk Reduction, %\n\n\n\n\nOverall Population\n\n\nAll Medicare Beneficiaries\n17.7 (15.2-20.5)\n20.3 (17.4-23.4)\n19.1 (16.3-22.0)\n1.2\n6.1\n\n\nAge Group\n\n\n65-74 Years\n14.0 (11.1-17.3)\n16.2 (13.0-19.8)\n14.9 (11.9-18.3)\n1.3\n7.9\n\n\n≥75 Years\n24.1 (19.7-28.9)\n27.3 (22.6-32.3)\n26.1 (21.6-31.0)\n1.1\n4.2\n\n\nSex\n\n\nFemale\n21.1 (18.0-24.5)\n23.3 (19.9-26.9)\n22.4 (19.2-25.9)\n0.8\n3.5\n\n\nMale\n14.3 (11.1-18.0)\n17.3 (13.6-21.4)\n15.6 (12.2-19.6)\n1.7\n9.6\n\n\nIncome Level\n\n\nLow (&lt;125% FPL)\n84.4 (74.6-91.6)\n86.8 (76.5-93.8)\n86.8 (76.5-93.8)\n0.0\n0.0\n\n\nMiddle (125%-400% FPL)\n18.1 (14.6-22.2)\n23.1 (18.7-28.1)\n20.4 (16.5-24.9)\n2.7\n11.6\n\n\nHigh (&gt;400% FPL)\n2.6 (0.9-5.9)\n2.7 (0.9-5.9)\n2.7 (0.9-5.9)\n0.0\n0.0\n\n\nRace and Ethnicity\n\n\nWhite\n17.1 (14.4-20.2)\n19.8 (16.6-23.3)\n18.8 (15.8-22.2)\n1.0\n4.9\n\n\nBlack\n22.2 (14.6-31.4)\n23.7 (15.9-33.0)\n21.6 (15.0-29.4)\n2.1\n8.9\n\n\nHispanic or Latino\n19.3 (10.5-31.1)\n23.3 (12.6-37.2)\n19.5 (10.6-31.5)\n3.8\n16.1\n\n\nOther Race and Ethnicity\n16.1 (6.2-31.8)\n16.1 (6.2-31.8)\n16.1 (6.2-31.8)\n0.0\n0.0\n\n\n\nNotes: MEPS 2022 cross-sectional estimates. Financial toxicity is defined as annual out-of-pocket health care expenditures (including premiums) exceeding 20% of post-subsistence income (income remaining after food, clothing, transportation, shelter, and other necessities). ‘Universal GLP-1 Receptor Agonist Adherence’ assumes 100% adherence to incretin mimetic therapy. ‘Inflation Reduction Act Implementation’ applies a $2,100 annual pharmacy cap to the Medicare Part D portion. Costs are reported in Jan 2026 US dollars. CIs calculated using Korn-Graubard beta intervals based on bootstrap standard errors (2000 replicates). ‘–’ = Suppressed due to statistical unreliability (insufficient sample size or variance instability).\n\n\n\n\n\n\n\n\n\n\n\n\nTable 5. Policy Efficiency Metrics Among Medicare Beneficiaries: Number Needed to Treat/Harm and Projected Cases of Financial Toxicity Prevented.\n\n\n\n\n\n\n\n\n\n\nEconomic Number Needed to Harm\nEconomic Number Needed to Treat\nProjected Cases Prevented, No.\n\n\n\n\nOverall\n\n\nOverall\n39\n81\n226,636\n\n\nAge Group\n\n\n65-74 Years\n45\n78\n148,864\n\n\n≥75 Years\n31\n88\n77,772\n\n\nSex\n\n\nFemale\n47\n124\n74,568\n\n\nMale\n33\n60\n152,068\n\n\nIncome Level\n\n\nLow (&lt;125% FPL)\n42\nNegl.\n0\n\n\nMiddle (125%-400% FPL)\n20\n37\n226,636\n\n\nHigh (&gt;400% FPL)\nNegl.\nNegl.\n0\n\n\nRace and Ethnicity\n\n\nWhite\n37\n103\n145,440\n\n\nBlack\n68\n48\n36,750\n\n\nHispanic or Latino\n25\n27\n44,446\n\n\nOther Race and Ethnicity\nNegl.\nNegl.\n0\n\n\n\nNotes: MEPS 2022 cross-sectional estimates. Economic Number Needed to Harm indicates the number of patients prescribed universal incretin mimetic (GLP-1 receptor agonist) therapy to cause one new case of financial toxicity. Economic Number Needed to Treat indicates the number of patients in the universal incretin mimetic cohort benefiting from the IRA cap to prevent one case of financial toxicity. Costs are reported in Jan 2026 US dollars. ‘Negl.’ = Negligible risk difference (&lt;0.5%).\n\n\n\n\n\n\n\n\n\n\n\n\nFigure 1. Survey-Weighted Financial Toxicity by Universal GLP-1RA Access Scenario Across Insurance Plans.\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nFigure 2. Prevalence of Financial Toxicity and Composition of Out-of-Pocket Costs Among Medicare Beneficiaries Under Universal GLP-1RA and IRA Policy Scenarios.\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nFigure 3. Changes in Financial Toxicity Prevalence Among Medicare Beneficiaries From Universal GLP-1RA to Inflation Reduction Act Scenarios by Demographic Subgroup.\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nFigure 4. Distribution of Insurance Coverage Types Among FDA-Eligible US Adults Across Racial and Economic Subgroups.\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nSupplementary Table 1. Comparative Survey-Weighted Annualized GLP-1RA Out-of-Pocket Cost Distributions Across the Baseline General Adult Population, Observed FDA-Eligible Cohort, and Simulated Universal Adherence Cohort by Insurance Type.\n\n\n\n\n\n\n\n\n\n\nBaseline General Adult Population\nObserved FDA-Eligible Cohort\nSimulated Universal Adherence Cohort\n\n\n\n\nMedicaid or Dual Eligible\n\n\nMedian Annual OOP\n$0\n$0\n$0\n\n\nIQR\n$0-$42\n$0-$54\n$0-$48\n\n\n10th-90th Percentiles\n$0-$149\n$0-$545\n$0-$362\n\n\nMedicare\n\n\nMedian Annual OOP\n$473\n$590\n$328\n\n\nIQR\n$217-$1067\n$286-$1365\n$98-$439\n\n\n10th-90th Percentiles\n$44-$2104\n$48-$2106\n$0-$1087\n\n\nPrivate/Commercial\n\n\nMedian Annual OOP\n$326\n$338\n$135\n\n\nIQR\n$121-$362\n$169-$362\n$22-$362\n\n\n10th-90th Percentiles\n$39-$489\n$0-$676\n$0-$435\n\n\n\nNotes: MEPS 2022 cross-sectional estimates. Survey-weighted annualized GLP-1RA out-of-pocket distributions are shown as median, IQR, and 10th-90th percentile range by insurance type in Jan 2026 US dollars. Baseline General Adult Population = all US adults currently using GLP-1RA therapy with observed daily out-of-pocket costs. Observed FDA-Eligible Cohort = observed GLP-1RA users within the insured eligible population meeting clinical eligibility criteria: obesity (body mass index &gt;=30 kg/m^2 or documented clinical obesity diagnosis) or overweight (body mass index 27.0-29.9 kg/m^2) with at least one qualifying weight-related comorbidity. Simulated Universal Adherence Cohort = the insured eligible population after universal-adherence assignment, combining observed and PMM-imputed GLP-1RA daily costs under the same clinical eligibility criteria.\n\n\n\n\n\n\n\n\n\n\n\n\nSupplementary Table 2. Projected Annual Out-of-Pocket Savings for Medicare Beneficiaries Stratified by Demographic Subgroups with 95% Bootstrap CIs.\n\n\n\n\n\n\n\n\n\n\nPre-IRA OOP\nPost-IRA OOP\nNet Savings\n% Benefiting\nSavings (Beneficiaries)\n\n\n\n\nOverall Population\n\n\nOverall\n$3959 (3624-4325)\n$3757 (3429-4115)\n$203 (143-287)\n9.3 (7.6-11.3)\n$2172 (1649-2861)\n\n\nAge Group\n\n\n65-74 Years\n$4011 (3625-4437)\n$3826 (3455-4237)\n$185 (122-280)\n9.2 (6.9-11.8)\n$2014 (1461-2778)\n\n\n≥75 Years\n$3871 (3310-4527)\n$3638 (3088-4287)\n$233 (139-389)\n9.6 (6.9-12.9)\n$2428 (1602-3679)\n\n\nSex\n\n\nFemale\n$4023 (3675-4405)\n$3845 (3508-4215)\n$178 (118-268)\n9.9 (7.4-12.9)\n$1795 (1282-2515)\n\n\nMale\n$3894 (3416-4438)\n$3667 (3207-4191)\n$227 (137-377)\n8.7 (6.4-11.5)\n$2609 (1727-3941)\n\n\nIncome Level\n\n\nLow (&lt;125% FPL)\n$2742 (2140-3513)\n$2498 (1935-3224)\n$244 (105-569)\n7.0 (4.0-11.2)\n$3491 (1856-6566)\n\n\nMiddle (125%-400% FPL)\n$3499 (3038-4031)\n$3269 (2824-3784)\n$230 (139-383)\n10.1 (7.4-13.5)\n$2273 (1554-3325)\n\n\nHigh (&gt;400% FPL)\n$4702 (4192-5273)\n$4537 (4039-5096)\n$165 (106-256)\n9.0 (6.5-12.1)\n$1829 (1248-2681)\n\n\nRace and Ethnicity\n\n\nWhite\n$4181 (3781-4624)\n$3975 (3582-4412)\n$206 (148-286)\n9.0 (7.2-11.1)\n$2285 (1736-3006)\n\n\nBlack\n$2927 (2282-3756)\n$2679 (2108-3405)\n$248 (--)\n11.6 (4.4-23.7)\n$2132 (--)\n\n\nHispanic or Latino\n$3098 (2220-4323)\n$2933 (2074-4147)\n$165 (--)\n12.4 (4.3-26.1)\n$1334 (624-2850)\n\n\nOther Race and Ethnicity\n$3049 (1945-4780)\n$3006 (1905-4743)\n$43 (--)\n3.7 (0.7-10.9)\n$1169 (--)\n\n\n\nNotes: MEPS 2022 cross-sectional estimates apply specifically to the Medicare beneficiary population. Values are Mean (95% CI). Costs are reported in Jan 2026 US dollars. CIs for costs use bootstrap standard errors with log-transformation; CIs for proportions use Korn-Graubard beta intervals. ‘–’ = Suppressed due to statistical unreliability (insufficient sample size or variance instability).\n\n\n\n\n\n\n\n\n\n\n\n\nSupplementary Table 3. Sensitivity Analysis: Projected Financial Toxicity (FT) in All US Adults Eligible for Incretin-Based Weight Management Therapies (Including Non-Medicare Populations). Note: Impact is diluted as ~40% of the population (Commercial/Medicaid) is ineligible for the IRA cap.\n\n\n\n\n\n\n\n\n\n\nBaseline (95% CI)\nUniversal GLP-1 Receptor Agonist (95% CI)\nPost-IRA (95% CI)\nAbsolute Reduction (ARR, %)\nRelative Reduction (RRR, %)\n\n\n\n\nOverall Population\n\n\nAll Patients\n18.0 (16.7-19.4)\n19.6 (18.2-21.1)\n19.2 (17.9-20.7)\n0.4\n1.8\n\n\nAge Group\n\n\n18-64 Years\n17.0 (15.3-18.8)\n18.2 (16.5-20.0)\n18.2 (16.5-20.0)\n0.0\n0.0\n\n\n65-74 Years\n16.8 (13.9-20.0)\n18.9 (15.9-22.3)\n17.8 (14.9-21.1)\n1.1\n5.9\n\n\n≥75 Years\n25.7 (21.5-30.2)\n28.6 (24.2-33.3)\n27.6 (23.3-32.1)\n1.0\n3.5\n\n\nSex\n\n\nFemale\n21.3 (19.6-23.1)\n22.9 (21.1-24.7)\n22.7 (20.9-24.4)\n0.2\n1.0\n\n\nMale\n14.4 (12.7-16.3)\n16.0 (14.1-18.0)\n15.5 (13.6-17.4)\n0.5\n3.2\n\n\nIncome Level\n\n\nLow (&lt;125% FPL)\n75.0 (70.7-79.0)\n78.5 (74.4-82.2)\n78.5 (74.4-82.2)\n0.0\n0.0\n\n\nMiddle (125%-400% FPL)\n16.7 (14.6-19.0)\n19.2 (16.9-21.6)\n18.4 (16.2-20.6)\n0.8\n4.4\n\n\nHigh (&gt;400% FPL)\n1.5 (0.8-2.4)\n1.6 (0.9-2.5)\n1.6 (0.9-2.5)\n0.0\n0.0\n\n\nRace and Ethnicity\n\n\nWhite\n17.5 (15.8-19.4)\n19.0 (17.1-21.0)\n18.7 (16.8-20.6)\n0.3\n1.8\n\n\nBlack\n22.9 (18.9-27.3)\n24.6 (20.6-29.0)\n24.2 (20.2-28.5)\n0.4\n1.8\n\n\nHispanic or Latino\n17.0 (14.0-20.4)\n19.0 (15.8-22.5)\n18.5 (15.4-21.9)\n0.5\n2.8\n\n\nOther Race and Ethnicity\n15.2 (10.5-20.9)\n16.9 (12.0-22.7)\n16.9 (12.0-22.7)\n0.0\n0.0\n\n\nInsurance Type\n\n\nMedicaid or Dual Eligible\n32.6 (28.6-36.8)\n34.3 (30.3-38.5)\n34.3 (30.3-38.5)\n0.0\n0.0\n\n\nMedicare\n17.7 (15.2-20.5)\n20.3 (17.4-23.4)\n19.1 (16.3-22.0)\n1.2\n6.1\n\n\nPrivate/Commercial\n12.9 (11.2-14.8)\n13.9 (12.2-15.8)\n13.9 (12.2-15.8)\n0.0\n0.0\n\n\n\nNotes: MEPS 2022 cross-sectional estimates. Costs are reported in Jan 2026 US dollars. CIs calculated using Korn-Graubard beta intervals based on bootstrap standard errors (2000 replicates). ‘–’ = Suppressed due to statistical unreliability (insufficient sample size or variance instability).\n\n\n\n\n\n\n\n\n\n\n\n\nSupplementary Table 4. Projected Incidence of Catastrophic Financial Toxicity (&gt;40% of Income) Among Medicare Beneficiaries.\n\n\n\n\n\n\n\n\n\n\nBaseline (95% CI)\nUniversal GLP-1 Receptor Agonist (95% CI)\nPost-IRA (95% CI)\nAbsolute Reduction (ARR, %)\nRelative Reduction (RRR, %)\n\n\n\n\nOverall Population\n\n\nAll Medicare Beneficiaries\n11.7 (9.8-13.8)\n12.9 (10.7-15.3)\n12.3 (10.3-14.5)\n0.6\n4.8\n\n\nAge Group\n\n\n65-74 Years\n8.1 (5.9-10.8)\n9.3 (6.9-12.2)\n8.8 (6.5-11.6)\n0.5\n5.4\n\n\n≥75 Years\n17.8 (14.2-21.9)\n18.9 (15.2-23.0)\n18.1 (14.6-22.1)\n0.8\n4.2\n\n\nSex\n\n\nFemale\n13.2 (11.1-15.6)\n14.5 (12.1-17.3)\n14.1 (11.8-16.8)\n0.4\n2.8\n\n\nMale\n10.1 (7.5-13.3)\n11.2 (8.3-14.6)\n10.4 (7.7-13.6)\n0.8\n7.3\n\n\nIncome Level\n\n\nLow (&lt;125% FPL)\n79.3 (69.8-87.0)\n84.1 (74.2-91.4)\n84.1 (74.2-91.4)\n0.0\n0.0\n\n\nMiddle (125%-400% FPL)\n8.3 (5.9-11.4)\n9.6 (6.7-13.2)\n8.3 (5.8-11.3)\n1.3\n14.0\n\n\nHigh (&gt;400% FPL)\n0.2 (0.0-1.1)\n0.5 (0.1-2.0)\n0.5 (0.1-2.0)\n0.0\n0.0\n\n\nRace and Ethnicity\n\n\nWhite\n10.5 (8.5-12.9)\n11.8 (9.5-14.4)\n11.3 (9.1-13.8)\n0.5\n4.3\n\n\nBlack\n19.0 (12.0-27.9)\n19.9 (12.7-28.7)\n17.8 (12.0-24.8)\n2.1\n10.6\n\n\nHispanic or Latino\n14.4 (7.1-24.9)\n15.8 (8.1-26.6)\n15.8 (8.1-26.6)\n0.0\n0.0\n\n\nOther Race and Ethnicity\n14.3 (5.1-29.5)\n14.3 (5.1-29.5)\n14.3 (5.1-29.5)\n0.0\n0.0\n\n\n\nNotes: MEPS 2022 cross-sectional estimates. Catastrophic toxicity defined as annual person-level out-of-pocket health care expenditures (including premiums) exceeding 40% of post-subsistence family income. Costs are reported in Jan 2026 US dollars. ‘–’ = Suppressed due to statistical unreliability (insufficient sample size or variance instability).\n\n\n\n\n\n\n\n\n\n\n\n\nSupplementary Figure 1. Annualized Out-of-Pocket Cost Density Distributions Before and After PMM Imputation by Insurance Type (Jan 2026 US dollars).\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nSupplementary Figure 2. Reductions in Catastrophic Financial Toxicity (&gt;40%) Among Medicare Beneficiaries by Demographic Subgroup."
  }
]